These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1358026)

  • 1. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy.
    Nielsen C; Gøtzsche PC; Nielsen CM; Gerstoft J; Vestergaard BF
    Antiviral Res; 1992 Jun; 18(3-4):303-16. PubMed ID: 1358026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population dynamics of HIV within an individual after treatment with zidovudine.
    McLean AR; Emery VC; Webster A; Griffiths PD
    AIDS; 1991 May; 5(5):485-9. PubMed ID: 1677807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
    Richman DD; Grimes JM; Lagakos SW
    J Acquir Immune Defic Syndr (1988); 1990; 3(8):743-6. PubMed ID: 2114476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.
    Land S; McGavin C; Lucas R; Birch C
    J Infect Dis; 1992 Nov; 166(5):1139-42. PubMed ID: 1402026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
    Ogino MT; Dankner WM; Spector SA
    J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 sensitivity to zidovudine and clinical outcome in children.
    Tudor-Williams G; St Clair MH; McKinney RE; Maha M; Walter E; Santacroce S; Mintz M; O'Donnell K; Rudoll T; Vavro CL
    Lancet; 1992 Jan; 339(8784):15-9. PubMed ID: 1345951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
    Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
    Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZT resistance in isolates of HIV.
    Richman DD
    Immunodefic Rev; 1991; 2(4):315-8. PubMed ID: 2059436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
    D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD
    Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Larder BA; Darby G; Richman DD
    Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.
    Land S; Terloar G; McPhee D; Birch C; Doherty R; Cooper D; Gust I
    J Infect Dis; 1990 Feb; 161(2):326-9. PubMed ID: 2299212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.
    St Clair MH; Hartigan PM; Andrews JC; Vavro CL; Simberkoff MS; Hamilton JD
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):891-7. PubMed ID: 8315574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen.
    Rübsamen-Waigmann H; Schröder B; Biesert L; Bauermeister CD; von Briesen H; Suhartono H; Zimmermann F; Brede HD; Regeniter A; Gerte S
    Infection; 1991; 19 Suppl 2():S77-82. PubMed ID: 1673119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antiviral therapy on the production of anti-human immunodeficiency virus-specific immunoglobulin in infants and children.
    Pollack H; Zhan MX; Moore T; Tao PZ; Krasinski K; Borkowsky W
    J Infect Dis; 1994 Oct; 170(4):1003-6. PubMed ID: 7930694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
    Larder BA; Kellam P; Kemp SD
    AIDS; 1991 Feb; 5(2):137-44. PubMed ID: 1709563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S; De Pasquale MP; Milazzo L; Moscatelli G; Bulgheroni E; Citterio P; d'Arminio-Monforte A; Moroni M; Galli M
    Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.